摘要：

目的：研究甲苯磺酸索拉非尼（Sorafenib tosylate，ST）对口腔鳞状细胞癌（oral squamous cell carcinoma，OSCC）CAL-27细胞自噬、增殖、迁移的影响。方法：采用不同浓度的索拉非尼处理CAL-27细胞，使用CCK-8法和细胞克隆形成实验检测其增殖活性；通过细胞划痕实验检测其对CAL-27细胞迁移能力的影响；通过蛋白质印迹法检测Beclin1、LC3B、PCNA的表达。用自噬激活剂雷帕霉素（rapamycin，RA）预处理CAL-27细胞，检测激活自噬后索拉非尼对CAL-27细胞增殖、迁移和Beclin-1、LC3B、PCNA表达的影响。结果：与对照组相比，索拉非尼可显著抑制CAL-27的细胞增殖和迁移；索拉非尼使Beclin-1和PCNA表达下降、LC3B的胞质形式LC3Ⅰ和LC3B的脂质形式LC3Ⅱ的表达上升；但用RA预处理CAL-27细胞激活自噬后，索拉非尼对CAL-27细胞的增殖、迁移的抑制作用被削弱，Beclin-1和PCNA的表达上升，LC3B的胞质形式LC3Ⅰ和LC3B的脂质形式LC3Ⅱ的表达下降。结论：索拉非尼可能通过下调Beclin-1抑制自噬，从而抑制CAL-27细胞的增殖和迁移，为OSCC提供潜在的治疗策略。

关键词: 口腔鳞状细胞癌, 自噬, 增殖, 迁移, 索拉非尼

Abstract:

Objective: To study the effect of Sorafenib tosylate (ST) on autophagy, proliferation and migration of CAL-27 cells in oral squamous cell carcinoma (OSCC). Methods: The CAL-27 cells were treated with different concentrations of ST, and their proliferation activity was detected by CCK-8 and cell clone formation assay; the effect of the CAL-27 cells migration was detected by cell wound scratch assay; the expressions of Beclin1, LC3B and PCNA were detected by western blotting. The CAL-27 cells were pretreated with the autophagy activator rapamycin, and the effects of ST on the proliferation, migration and expression of Beclin1, LC3B and PCNA in CAL-27 cells were detected after activation of autophagy. Results: Compared with the control group, ST significantly inhibited the proliferation and migration of the CAL-27 cells. ST decreased the expressions of Beclin-1, PCNA and increased the expressions of the cytoplasmic form LC3Ⅰ and the lipid form LC3Ⅱ of LC3B. However, when the CAL-27 cells were pretreated with RA to activate autophagy, the inhibitory effect of ST on proliferation and migration of the CAL-27 cells were weakened, the expressions of Beclin-1 and PCNA were increased, and the expressions of the cytoplasmic form LC3Ⅰ and the lipid form LC3Ⅱ of LC3B were decreased. Conclusion: ST may inhibit the proliferation and migration of CAL-27 cells by down-regulating Beclin-1, and inhibiting autophagy. Inhibition of autophagy may be a potential therapeutic strategy for OSCC.

Key words: oral squamous cell carcinoma, autophagy, proliferation, migration, Sorafenib tosylate

中图分类号: 

• R782